DSGN
NASDAQ HealthcareDesign Therapeutics, Inc. - Common Stock
Biotechnology
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
�� 市场数据
| 价格 | $13.12 |
|---|---|
| 成交量 | 300,913 |
| 市值 | 809.14M |
| 贝塔系数 | 1.580 |
| RSI（14日） | 75.7 超买 |
| 200日均线 | $7.92 |
| 50日均线 | $10.80 |
| 52周最高 | $13.50 |
| 52周最低 | $3.10 |
| Forward P/E | -7.65 |
| Price / Book | 3.73 |
🎯 投资策略评分
DSGN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (78/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🔪 Falling Knife (5/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 DSGN in your text
粘贴任何文章、记录或帖子 — 工具将提取 DSGN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.